Compare · BSX vs CARL
BSX vs CARL
Side-by-side comparison of Boston Scientific Corporation (BSX) and Carlsmed Inc. (CARL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and CARL operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $60.85B, about 127.5x CARL ($477.4M).
- BSX has been more active in the news (17 items in the past 4 weeks vs 7 for CARL).
- BSX has more recent analyst coverage (25 ratings vs 6 for CARL).
- Company
- Boston Scientific Corporation
- Carlsmed Inc.
- Price
- -
- -
- Market cap
- $60.85B
- $477.4M
- 1M return
- -8.74%
- -
- 1Y return
- -56.53%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 17
- 7
- Recent ratings
- 25
- 6
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- Boston Scientific Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits
- Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes
- SEC Form FWP filed by Boston Scientific Corporation
- SEC Form 424B5 filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- Chairman, President & CEO Mahoney Michael F received a gift of 252,241 shares (SEC Form 4)
- SVP, Chief HR Officer O'Sullivan Miriam converted options into 3,871 shares and covered exercise/tax liability with 1,872 shares, increasing direct ownership by 11% to 19,565 units (SEC Form 4)
- Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
- SEC Form 10-Q filed by Boston Scientific Corporation
- SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
Latest CARL
- Carlsmed to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by Carlsmed Inc.
- Carlsmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Carlsmed® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance
- Chief Operating Officer Bertolini Jeffrey exercised 747 shares at a strike of $5.92 and sold $11,317 worth of shares (747 units at $15.15) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Bertolini Jeffrey exercised 243 shares at a strike of $2.23 and sold $3,839 worth of shares (243 units at $15.80) as part of a pre-agreed trading plan (SEC Form 4)
- Carlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026
- SEC Form 144 filed by Carlsmed Inc.
- Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System
- Chief Operating Officer Bertolini Jeffrey sold $10,749 worth of shares (747 units at $14.39) as part of a pre-agreed trading plan (SEC Form 4)